prednisolone + amoxicillin + clavulanate

This investigational combination therapy, studied by the University of Chicago, consists of the systemic corticosteroid prednisolone and the antibiotic combination amoxicillin/clavulanate. It is being evaluated in a Phase 4 clinical trial (titled 'Steroids and Antibiotics for Childhood OSAS') for the treatment of mild obstructive sleep apnea syndrome (OSAS) in children aged 18 months to 12 years. The therapeutic rationale is to reduce the size of hypertrophic tonsils and adenoids by addressing both inflammation and potential chronic bacterial infection within the lymphoid tissues. By shrinking these tissues, the treatment aims to alleviate airway obstruction and improve sleep symptoms, potentially serving as a non-surgical alternative or adjunct to adenotonsillectomy, which is the standard first-line treatment for pediatric OSA.

Brand names

Augmentin

Other names

Steroids and Antibiotics for Childhood OSAS